Novo Nordisk A/S (VIE:NNO2)
Austria · Delayed Price · Currency is EUR | Market Cap | 180.45B +4.7% |
| Revenue (ttm) | 44.06B +5.6% |
| Net Income | 15.57B +4.8% |
| EPS | 3.50 +5.0% |
| Shares Out | n/a |
| PE Ratio | 11.59 |
| Forward PE | 15.37 |
| Dividend | 1.57 (3.85%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 6,405 |
| Open | 40.83 |
| Previous Close | 39.15 |
| Day's Range | 40.61 - 41.70 |
| 52-Week Range | 30.01 - 55.08 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem
Eli Lilly should request approval for retatrutide early next year. This medicine could help the company expand the weight loss market.
Novo Nordisk price target lowered to DKK 310 from DKK 330 at Citi
Citi lowered the firm’s price target on Novo Nordisk (NVO) to DKK 310 from DKK 330 and keeps a Neutral rating on the shares. The firm views the company’s Q2…
Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market
Eli Lilly and Novo Nordisk have persuaded a U.S. federal judge to dismiss a lawsuit by a compound drug maker that accused the pharmaceutical giants of illegally blocking access to customized versions ...
Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk
The holding company beat out incumbent WPP for the U.S. account valued at $520 million.
Why Is Everyone Talking About Novo Nordisk?
Novo Nordisk recently experienced a clinical setback. Despite financial results mostly in line with expectations, one product fell short.
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, they punished Novo a day earlier – underscoring a growin...
33 stocks to bet on foreign markets continuing to beat the S&P 500
Surprisingly, many foreign markets are way ahead of the U.S. in year-to-date performance.
Novo Nordisk price target raised to $47 from $45 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Novo Nordisk (NVO) to $47 from $45 and keeps a Market Perform rating on the shares. Novo Nordisk delivered…
How Novo Nordisk's CEO Says He Is Shifting the Company's Perspective
Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment
Bank of America CEO Brian Moynihan said the company has dramatically increased its investment in medications such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound.
Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 Outlook
Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 Outlook
European Stocks Subdued as HSBC and Novo Nordisk Lead Declines
European stocks traded steady near a record high as falls in HSBC Holdings Plc and Novo Nordisk A/S helped erase early gains.
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
The Danish company developed the most lucrative new drug the world had ever seen. Then America's Eli Lilly outmaneuvered it and took control of the diet-drug market.
Novo Nordisk Wins Dutch Court Injunction Against Compounded Semaglutide Nasal Spray
(RTTNews) - Novo Nordisk A/S (NVO) said Wednesday it secured a preliminary injunction from the District Court of The Hague against Ceban Ziekenhuisfarmacie B.V., ordering the company to immediately st...
Novo Nordisk Stock (NVO) Recovers as Earnings Surprise to the Upside
The company beat Wall Street forecasts across the board.
Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case
Danish drugmaker Novo Nordisk said on Wednesday it had won a preliminary injunction against Ceban Ziekenhuisfarmacie B.V. from a district court in the Netherlands in a patent infringement...
Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative Deals
Chief Executive Mike Doustdar's comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.
Novo Nordisk Earnings Call Transcript: Q2 2026
Adjusted sales rose 7% in Q2 2026, led by strong GLP-1 and obesity franchise growth, despite U.S. pricing pressure and increased self-pay mix. The Wegovy pill saw rapid global uptake, and the pipeline advanced with key trial readouts and new launches. Guidance for 2026 was raised, but headwinds remain.
Novo Nordisk Quarterly report: Q2 2026
Novo Nordisk has published its Q2 2026 quarterly earnings report on August 5, 2026.
Novo Nordisk Slides: Q2 2026
Novo Nordisk has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Novo Nordisk (NVO) Raises Guidance Amid Mixed Market Reactions
Novo Nordisk (NVO) Raises Guidance Amid Mixed Market Reactions
Novo Nordisk CEO addresses investors' high Wegovy pill expectations
Novo Nordisk hikes its 2026 outlook, but investors focus more on quarterly sales of the Danish pharma giant's Wegovy weight loss pill, which came in slightly lower than expected. CEO Mike Doustdar add...
Novo Nordisk CEO addresses investors' high Wegovy pill expectations
Novo Nordisk hikes its 2026 outlook, but investors focus more on quarterly sales of the Danish pharma giant's Wegovy weight loss pill, which came in slightly lower than expected. CEO Mike Doustdar add...
Novo Nordisk's raised forecast fails to change the debate over its obesity business
Novo Nordisk raised its full year outlook late Tuesday. Analysts said the better-than-expected quarter benefited from rebate adjustments and other temporary factors, while obesity drug sales were larg...
Novo CEO faces investor grilling after outlook hike soured by pipeline concerns
Novo Nordisk CEO Mike Doustdar faces investors and analysts on Wednesday under pressure to restore confidence in the drugmaker's longer-term growth prospects after an upgraded 2026 outlook failed to...